RCUS Jul 2024 15.000 call
| Previous close | 3.0100 |
| Open | 3.0100 |
| Bid | 1.7500 |
| Ask | 4.9000 |
| Strike | 15.00 |
| Expiry date | 2024-07-19 |
| Day's range | 3.0100 - 3.0100 |
| Contract range | N/A |
| Volume | |
| Open interest | 422 |
- Business Wire
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
FOSTER CITY, Calif. & HAYWARD, Calif., June 02, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody zimberelimab, FOLFOX chemotherapy and bevacizumab (EZFB) in third-line metastatic colorectal cancer (mCRC). These results will be presented today during an oral session
- Business Wire
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
FOSTER CITY, Calif. & HAYWARD, Calif., June 01, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study. These updated data show consistent objective response rate (ORR) and provide mature progression-free survival (PFS) in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma (upper GI cancers). The
Simply Wall St.It's Unlikely That Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Will See A Huge Pay Rise This Year
Key Insights Arcus Biosciences' Annual General Meeting to take place on 6th of June Salary of US$650.0k is part of CEO...
